COVID-19 Disease Burden in the Omicron Variant-Dominated Endemic Phase: Insights from the ROUTINE-COV19 Study Using Real-World German Statutory Health Insurance Data
- PMID: 40143351
- PMCID: PMC11945757
- DOI: 10.3390/v17030424
COVID-19 Disease Burden in the Omicron Variant-Dominated Endemic Phase: Insights from the ROUTINE-COV19 Study Using Real-World German Statutory Health Insurance Data
Abstract
The ROUTINE-COV19 study explores the burden of COVID-19 in Germany during the early endemic phase, assessing disease patterns and their impact on the healthcare system from 1 July 2022 to 30 June 2023. Using anonymized statutory health insurance data from over 3 million individuals in Thuringia and Saxony, COVID-19 cases were identified through diagnostic codes, with severe and critical cases defined by hospitalization and intensive care criteria. The study focused on high-risk populations as identified by the German Immunization Technical Advisory Group. During the study period, 414,648 new COVID-19 cases were documented, with peaks in October 2022 and March 2023. Severe cases occurred at a rate of 241.6 per 100,000 persons, with in-hospital mortality exceeding 12%. Critical cases requiring intensive care had an in-hospital mortality rate of 32.2%. COVID-19-related hospitalizations averaged 9.94 days, generating direct costs of EUR 64.9 million, while indirect costs from work absenteeism amounted to EUR 454.3 million, representing 7.5% of all-cause absenteeism costs. Despite entering an endemic phase, COVID-19 continues to pose a substantial burden, particularly among older adults and those with pre-existing cardiovascular conditions.
Keywords: COVID-19 case severity; COVID-19 endemic phase; economic impact; healthcare burden; in-hospital COVID-19 case mortality; statutory health insurance data Germany.
Conflict of interest statement
C.D.S. reports grants and personal fees from AstraZeneca; personal fees and non-financial support from B. Braun Melsungen; personal fees from BioNTech; grants, personal fees, and non-financial support from Gilead Sciences; grants and personal fees from Janssen-Cilag; personal fees from Eli Lilly; personal fees from Formycon; personal fees from Pfizer; personal fees from Roche and others from Apeiron; grants and personal fees from MSD; grants from Cepheid; personal fees from GSK; personal fees from Molecular partners; personal fees from Pfizer and others from Eli Lilly; personal fees from SOBI during the conduct of the study; personal fees from AbbVie; personal fees from MSD; personal fees from Synairgen; personal fees from Shionogi; and grants and personal fees from ViiV Healthcare, outside the submitted work. C.L. reports receiving grants from Gilead, receiving advisory fees from ViiV, Pfizer, Novartis, BioNTech, Merck Sharp & Dohme, and Gilead, and receiving non-financial support from Gilead outside the submitted work. No other disclosures than those related to the affiliations listed were reported by the other authors.
Figures




Similar articles
-
The health economic burden of dengue in Germany: a retrospective analysis of statutory health insurance claims data.Infect Dis Now. 2025 Sep;55(6):105107. doi: 10.1016/j.idnow.2025.105107. Epub 2025 Jun 18. Infect Dis Now. 2025. PMID: 40541700
-
Disease and Economic Burden of COVID-19 in the Prevaccine Era in a Fragmented Health System: The Argentine Case.Value Health Reg Issues. 2025 Jul;48:101137. doi: 10.1016/j.vhri.2025.101137. Epub 2025 Jun 2. Value Health Reg Issues. 2025. PMID: 40460714
-
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3. Cochrane Database Syst Rev. 2022. PMID: 35593186 Free PMC article.
-
Quantifying all-cause healthcare resource utilization and costs of children with mild-to-moderate long COVID in France.J Med Econ. 2025 Dec;28(1):1002-1013. doi: 10.1080/13696998.2025.2525002. Epub 2025 Jul 3. J Med Econ. 2025. PMID: 40574623
-
Risk of thromboembolism in patients with COVID-19 who are using hormonal contraception.Cochrane Database Syst Rev. 2023 Jan 9;1(1):CD014908. doi: 10.1002/14651858.CD014908.pub2. Cochrane Database Syst Rev. 2023. Update in: Cochrane Database Syst Rev. 2023 May 15;5:CD014908. doi: 10.1002/14651858.CD014908.pub3. PMID: 36622724 Free PMC article. Updated.
References
-
- Farrokhi M., Khankeh H., Saatchi M., Hadinejad Z., Ahmadi-Mazhin S., Mohsenzadeh Y., Nazdik Z.M., Shojafard J., Pourvakhshoori N., Ahmadi S. The Effect of the COVID-19 Pandemic on Environmental Health (Two Sides of the Same Coin): A Systematic Review. Disaster Med. Public Health Prep. 2023;17:e499. doi: 10.1017/dmp.2023.139. - DOI - PubMed
-
- The COVID-19 Pandemic and Continuing Challenges to GLOBAL Health. [(accessed on 14 October 2024)]. Available online: https://www.who.int/about/funding/invest-in-who/investment-case-2.0/chal....
-
- Machado B.A.S., Hodel K.V.S., Fonseca L.M.D.S., Pires V.C., Mascarenhas L.A.B., da Silva Andrade L.P.C., Moret M.A., Badaró R. The Importance of Vaccination in the Context of the COVID-19 Pandemic: A Brief Update Regarding the Use of Vaccines. Vaccines. 2022;2022:591. doi: 10.3390/vaccines10040591. - DOI - PMC - PubMed
Publication types
MeSH terms
Supplementary concepts
Grants and funding
LinkOut - more resources
Full Text Sources
Medical